Liu Y, Li Y, Zang J, Zhang T, Li Y, Tan Z, et al. CircOGDH is a penumbra biomarker and therapeutic target in acute ischemic stroke. Circ Res. 2022;130(6):907–24. [Crossref] [Google Scholar] [PubMed].

Article  CAS  PubMed  Google Scholar 

Li DH, Li H, Song C. Therapeutic role of edaravone dexborneol injection in acute ischemic stroke and its influence on nerve function. Indian J Pharm Sci. 2024;86(3):171–7.

Google Scholar 

Hu X, Qian Z, Chen J, Chen M, Zhong W, Shen C, Hu Z, Li R. Effects of Edaravone Dexborneol on neurological function and serum inflammatory factor levels in patients with acute anterior circulation large vessel occlusion stroke. Transl Neurosci. 2023;14:20220312. https://doi.org/10.1515/tnsci-2022-0312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24:351–71.

Article  PubMed  Google Scholar 

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American heart association/american stroke association. Stroke. 2019;50(12):e344–418.

Article  PubMed  Google Scholar 

Nie X, Leng X, Miao Z, Fisher M, Liu L. Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke. Stroke. 2023;54(3):873–81.

Article  CAS  PubMed  Google Scholar 

Chen W, Zhang H, Li Z, Deng Q, Wang M, Chen Y, Zhang Y. Effects of Edaravone Dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke. BMC Neurol. 2024;24:209. https://doi.org/10.1186/s12883-024-03712-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Wang Y, Wang A, et al. Safety and efficacy of Edaravone Dexborneol versus Edaravone for patients with acute ischemic stroke: a phase II, multicenter, randomized, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019;4:e000221. https://doi.org/10.1136/svn-2018-000221.

Article  Google Scholar 

Wu HY, Tang Y, Gao LY, Sun WX, Hua Y, Yang SB, Zhang ZP, Liao GY, Zhou QG, Luo CX, et al. The synergetic effect of Edaravone and Borneol in the rat model of ischemic stroke. Eur J Pharmacol. 2014;740:522–31. https://doi.org/10.1016/j.ejphar.2014.06.035.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, Ren J, Yang S, Chen R, Zhu S, Feng X. Sublingual Edaravone Dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial. JAMA Neurol. 2024;81(4):319–26.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, Chen H, Ji Y, Xu J, Geng D, Zhu R. Edaravone Dexborneol versus Edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial. Stroke. 2021;52(3):772–80.

Article  CAS  PubMed  Google Scholar 

Lapchak PA. A critical assessment of Edaravone acute ischemic stroke efficacy trials: is Edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fidalgo M, Pires JR, Viseu I, Magalhaes P, Gregorio H, Afreixo V, Gregorio T. Edaravone for acute ischemic stroke–Systematic review with meta-analysis. Clin Neurol Neurosurg. 2022;219:107299.

Article  PubMed  Google Scholar 

Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, Ibayashi S, Iida M. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci. 2004;221(1–2):11–7.

Article  CAS  PubMed  Google Scholar 

Pérez-González A, Galano A. OH radical scavenging activity of edaravone: mechanism and kinetics. J Phys Chem B. 2011;115(5):1306–14.

Article  PubMed  Google Scholar 

Wang LF, Zhang HY. A theoretical investigation on DPPH radical-scavenging mechanism of Edaravone. Bioorg Med Chem Lett. 2003;13(21):3789–92.

Article  CAS  PubMed  Google Scholar 

Shen G, Lou C, Li Q, Zhao B, Luo Y, Wu F, Jiao D, Fang M, Geng Y. Edaravone Dexborneol alleviates cerebral ischemia–reperfusion injury through NF-κB/NLRP3 signal pathway. Anat Rec. 2024;307(2):372–84.

Article  CAS  Google Scholar 

Li L, He G, Shi M, Zhu J, Cheng Y, Chen Y, Chen J, Xue Q. Edaravone Dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS). Eur J Pharmacol. 2023;957:176036.

Article  CAS  PubMed  Google Scholar 

Xiao P, Huang H, Zhao H, Liu R, Sun Z, Liu Y, Chen N, Zhang Z. Edaravone Dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of Nrf2/HO-1/GPX4 signaling. Free Radic Biol Med. 2024;217:116–25.

Article  CAS  PubMed  Google Scholar